Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296035 · ClinicalTrials.gov registry record · Phase 2
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01296035 is a Phase 2 study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 8 participants.
The verdict
NCT01296035, a Phase 2 study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
Interventions
- BIOLOGICAL Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296035
The ClinicalTrials.gov registry entry for NCT01296035 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panitumumab is the first listed.
NCT01296035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01296035 about?
NCT01296035 is a clinical study titled "Panitumumab and Gemcitabine in Relapsed Ovarian Cancer". This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
What is the current status of trial NCT01296035?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01296035?
The interventions under investigation include: Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01296035?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.